About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

University of Washington Reading & Dyslexia Research Program

Clinicaltrials.gov identifier NCT03945097

Recruitment Status Recruiting

First Posted May 10, 2019

Last update posted May 10, 2019

Study Description

Brief summary:

Subjects are recruited for a pre-kindergarten education program focusing on early literacy skills. Primary outcomes are improvement in letter knowledge and changes in brain response to text.

  • Condition or Disease:Reading Disability
  • Intervention/Treatment: Behavioral: preK
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 44 participants
  • Observational Model: Case-Control
  • Time Perspective: Prospective
  • Official Title: University of Washington Reading & Dyslexia Research Program
  • Estimated Study Start Date: May 2019
  • Estimated Primary Completion Date: June 2021
  • Estimated Study Completion Date: June 2021
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: Letters
Education program focuses on learning letters.
Behavioral: preK
Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
Outcome Measures
  • Primary Outcome Measures: 1. Letter Knowledge [ Time Frame: Within 2 weeks post intervention ]
    Knowledge of letter names and sounds. This is computed as percent correct (out of 52). Each child is shown a flash card with each upper case letter and asked to name it and say its sound
Eligibility Criteria
  • Ages Eligible for Study: 60 to 72 Months (Child)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers:
  • Sampling Method: Non-Probability Sample
  • Study Population: Typically developing children
Criteria

Inclusion Criteria: Typically developing children enrolled before kindergarten.

- Typically developing child between 60 and 72 months of age

- Has not yet begun Kindergarten

Exclusion Criteria:

- Reported neurological or psychiatric condition.

- Claustrophobia. ADHD

Contacts and Locations
Contacts

Contact: Patrick Donnelly 206-685-9365 pdonne@uw.edu

Locations

United States, Washington
University of Washignton
Seattle

Sponsors and Collaborators

University of Washington

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Investigators

Principal Investigator: Jason Yeatman, PhD University of Washington

More Information
  • Responsible Party: University of Washington
  • ClinicalTrials.gov Identifier: NCT03945097 History of Changes
  • Other Study ID Numbers: STUDY00000516, 1R21HD092771-01A1
  • First Posted: May 10, 2019 Key Record Dates
  • Last Update Posted: May 10, 2019
  • Last Verified: May 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Dyslexia